Discontinuation of injectable disease-modifying therapy (DMT) for multiple sclerosis (MS) after a long period of relapse freedom is frequently considered, but data on post-cessation disease course are lacking.(1) To compare time to first relapse and disability progression among 'DMT stoppers' and propensity-score matched 'DMT stayers' in the MSBase Registry; (2) To identify predictors of time to first relapse and disability progression in DMT stoppers.Inclusion criteria for DMT stoppers were: age ?18?years; no relapses for ?5?years at DMT discontinuation; follow-up for ?3?years after stopping DMT; not restarting DMT for ?3?months after discontinuation. DMT stayers were required to have no relapses for ?5?years at baseline, and were propensi...
Background Discontinuation of injectable diseasemodifying therapy (DMT) for multiple sclerosis (MS) ...
Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large ...
International audienceObjectives: To evaluate the rate of return of disease activity after cessation...
Discontinuation of injectable disease-modifying therapy (DMT) for multiple sclerosis (MS) after a lo...
Background Discontinuation of injectable diseasemodifying therapy (DMT) for multiple sclerosis (MS) ...
Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large ...
International audienceObjectives: To evaluate the rate of return of disease activity after cessation...
Discontinuation of injectable disease-modifying therapy (DMT) for multiple sclerosis (MS) after a lo...
Background Discontinuation of injectable diseasemodifying therapy (DMT) for multiple sclerosis (MS) ...
Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large ...
International audienceObjectives: To evaluate the rate of return of disease activity after cessation...